Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients

Background: The interassay variability and inconsistency of plasma beta-amyloid (A beta) measurements among centers are major factors precluding the interpretation of results and a substantial obstacle in the meta-analysis across studies of this biomarker. The goal of this investigation was to address these problems by improving the performance of the bioanalytical method. Methods: We used the Luminex immunoassay platform with a multiplex microsphere-based reagent kit from Innogenetics. A robotic pipetting system was used to perform crucial steps of the procedure. The performance of this method was evaluated using two kit control samples and two quality control plasma samples from volunteer donors, and by retesting previously assayed patient samples in each run. This setup was applied to process 2454 patient plasma samples from the Alzheimer's Disease Neuroimaging Initiative study biofluid repository. We have additionally evaluated the correlations between our results and cerebrospinal fluid (CSF) biomarker data using mixed-effects modeling. Results: The average precision values of the kit controls were 8.3% for A beta(1-40) and 4.0% for A beta(1-42), whereas the values for the plasma quality controls were 6.4% for A beta(1-40) and 4.8% for A beta(1-42). From the test-retest evaluation, the average precision was 7.2% for A beta(1-40) and 4.5% for A beta(1-42). The range of final plasma results for Alzheimer's Disease Neuroimaging Initiative patients was 13 to 372 pg/mL (median: 164 pg/mL) for A beta(1-40) and 3.5 to 103 pg/mL (median: 39.3 pg/mL) for A beta(1-42). We found that sample collection parameters (blood volume and time to freeze) have a small, but significant, influence on the result. No significant difference was found between plasma A beta levels for patients with Alzheimer's disease and healthy control subjects. We have determined multiple significant correlations of plasma A beta(1-42) levels with CSF biomarkers. The relatively strongest, although modest, correlation was found between plasma A beta(1-42) levels and CSF p-tau(181)/A beta(1-42) ratio in patients with mild cognitive impairment. Plasma A beta(1-40) correlations with CSF biomarkers were weaker and diminished completely when we used longitudinal data. No significant correlations were found for the plasma A beta(1-42)/A beta(1-40) ratio. Conclusions: The precision of our robotized method represents a substantial improvement over results reported in the literature. Multiple significant correlations between plasma and CSF biomarkers were found. Although these correlations are not strong enough to support the use of plasma A beta measurement as a diagnostic screening test, plasma A beta(1-42) levels are well suited for use as a pharmacodynamic marker. (C) 2012 The Alzheimer's Association. All rights reserved.